Literature DB >> 14564084

Significance of serum circulating hepatocyte growth factor in the development of carotid atherosclerosis.

Ryuichi Kawamoto1, Yuichiro Oka, Osamu Yoshida, Yaemi Takagi.   

Abstract

We investigated the relation between the serum concentration of HGF and carotid atherosclerosis. Serum concentrations of HGF were measured in 128 in-patients (mean age, 74 +/- 11 years) free from cardiac, liver and renal diseases, in addition to lung diseases, in the Medical Department of Nomura Municipal Hospital between August, 2000 and June, 2001. Carotid intima-media thickness (IMT) was evaluated by ultrasonography with a 7.5 MHz linear type B-mode probe. The results showed a significantly positive correlation between serum age and HGF concentrations in patients with carotid atherosclerosis (IMT > 1.0 mm) (r = 0.391, p = 0.005). On the other hand, there was no significant correlation between age and serum HGF concentration in those without carotid atherosclerosis (IMT </= 1.0 mm) (r = 0.157, p = 0.173). A general linear model analysis for HGF adjusted with other risk factors showed that the age-carotid atherosclerosis interactions were significantly associated with serum HGF (F [1.114] = 6.193; p = 0.014), in addition to age, systolic blood pressure (SBP), aniti-hypertensive drug use, diabetes mellitus and carotid atherosclerosis. In contrast, multiple regression analysis showed that serum HGF (beta = 0.160, p = 0.033) was independently associated with carotid atherosclerois, in addition to gender, age, SBP and HDL-cholesterol. These results suggest that increased serum HGF concentrations were associated with carotid atherosclerosis, independent of known risk factors for atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14564084     DOI: 10.5551/jat.10.154

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  5 in total

1.  Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative.

Authors:  Swapnil N Rajpathak; Tao Wang; Sylvia Wassertheil-Smoller; Howard D Strickler; Robert C Kaplan; Aileen P McGinn; Rachel P Wildman; Daniel Rosenbaum; Thomas E Rohan; Philipp E Scherer; Mary Cushman; Gloria Y F Ho
Journal:  Stroke       Date:  2010-03-04       Impact factor: 7.914

2.  Hepatocyte growth factor demonstrates racial heterogeneity as a biomarker for coronary heart disease.

Authors:  Suzette J Bielinski; Cecilia Berardi; Paul A Decker; Nicholas B Larson; Elizabeth J Bell; James S Pankow; Michele M Sale; Weihong Tang; Naomi Q Hanson; Christina L Wassel; Mariza de Andrade; Matthew J Budoff; Joseph F Polak; Hugues Sicotte; Michael Y Tsai
Journal:  Heart       Date:  2017-06-01       Impact factor: 5.994

3.  Hepatocyte growth factor inhibits VEGF-forkhead-dependent gene expression in endothelial cells.

Authors:  Md Ruhul Abid; Robert J Nadeau; Katherine C Spokes; Takashi Minami; Dan Li; Shou-Ching Shih; William C Aird
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09-11       Impact factor: 8.311

4.  Hemoglobin as a possible biochemical index of hypertension-induced vascular damage.

Authors:  Yuji Shimizu; Koichiro Kadota; Mio Nakazato; Yuko Noguchi; Jun Koyamatsu; Hirotomo Yamanashi; Mako Nagayoshi; Shuichi Nagata; Kazuhiko Arima; Takahiro Maeda
Journal:  J Physiol Anthropol       Date:  2016-01-28       Impact factor: 2.867

5.  Shrunken Pore Syndrome Is Associated With Increased Levels of Atherosclerosis-Promoting Proteins.

Authors:  Markus Sällman Almén; Jonas Björk; Ulf Nyman; Veronica Lindström; Magnus Jonsson; Magnus Abrahamson; AnnaLotta Schiller Vestergren; Örjan Lindhe; Gary Franklin; Anders Christensson; Anders Grubb
Journal:  Kidney Int Rep       Date:  2018-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.